The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy
Open accessAbstract
The therapeutic landscape for renal cell carcinoma (RCC) has changed drastically over the past several years with the emergence of molecularly targeted therapies. With previous prognostic and predictive tools based on studies of patients treated with cytokine therapies, confirmation of these prior methods and discovery of new markers in this new era of targeted therapy are of great importance. Alteration of the von Hippel-Lindau gene (VHL) by mutation, loss of heterozygosity, and promoter methylation has been found to be important to RCC pathogenesis. In this review, we discuss the potential role of VHL mutation as a prognostic and predictive marker for RCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Mutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-85 · Cited by 1,730
The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma
Kaelin, W. G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1865 · Cited by 336
Cited by
Epigenetic plasticity and the hallmarks of cancer
Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340
“Angiogenesis may be rooted in hypermethylationof the vonHippel–Lindau (VHL) tumor suppressor gene promoter (96).”
BackgroundLC3/GABARAP family proteins: autophagy‐(un)related functions
Schaaf, M. B. E., Keulers, T. G., Vooijs, M. A., & Rouschop, K. M. A. (2016) · The FASEB Journal · doi:10.1096/fj.201600698r · Cited by 648
The immunology of renal cell carcinoma
Díaz-Montero, C. M., Rini, B. I., & Finke, J. H. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0316-3 · Cited by 442
Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.2627 · Cited by 393
Radiogenomics: bridging imaging and genomics
Bodalal, Z., Trebeschi, S., Nguyen-Kim, T. D. L., Schats, W., & Beets-Tan, R. (2019) · Abdominal Radiology · doi:10.1007/s00261-019-02028-w · Cited by 310
Metadata
- Authors
- Cowey, C. L., & Rathmell, W. K.
- Venue
- Current Oncology Reports
- Published
- 2009-02-10
- Volume
- 11
- Issue
- 2
- Pages
- 94-101
- ISSN
- 1523-3790 (ISSN-L)
- 1534-6269
- OpenAlex
- W2165647907
- Cited by
- 165
- References
- 5
- FWCI
- 5.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy. https://app.cochat.ai/papers/10.1007/s11912-009-0015-5
- The paper
- Cowey, C. L., & Rathmell, W. K. (2009). VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy. Current Oncology Reports. https://doi.org/10.1007/s11912-009-0015-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.